afrayem:
Spent almost the entire week-end researching BOCX and RJVN.
The deal between RJVN and BOCX regarding BioKinetex looks very peculiar. For all intents and purposes it looks like RJVN, a company with $939 in the bank as of its last filing acquired the rights for the super antibody they are sharing with BOCX from a Alberta company according to the release. What is strange about the deal is that RJVN on 12/6/2002 in its SEC filing showed 6,037,500 shares outstanding. About a month later they amended the filing to show 15,093,750 shares outstanding. BioKinetix, which was described as a Alberta company in a press release did not show up in a Google search. However this Biokinetix did; biokinetix.com . What is peculiar about Biokinetix is that they ONLY do rehabilitation work, no science or other stuff having to do with Super Antibodies. The question that then arises is “is this the same Biokinetix?”
Now, IF RJVN does have right to the Super Antibody it makes one wonder if it was previously owned by InNexus: innexuscorp.com, (also working on Super Antibodies) which applied for a listing on the TSX and was granted that listing on December 3, 2002 under their symbol CUS. On top of that, CUS just happens to be located in Vancouver as is the BOCX office I called. Could it be just a coincidence?
Now just to complicate matters a little further it APPEARS that this super antibody deal granted to CUS actually came through IMMKF or Immpheron biospace.com. Now IMMKF is actually in, you guessed it, Vancouver B.C. This seems like quite a coincidence as the following release seems to take us back to our original state of origin, Kentucky, where we first heard the name BioKinetix.
InNexus Inc. To Acquire "SuperAntibody" Technology
InNexus Corporation, a privately held, monoclonal antibody- development company, announced today that it has entered into an agreement to acquire the full commercial rights to "SuperAntibody Technology (SAT)" from ImmPheron Inc., a privately held company in Lexington, KY. Concurrent with the closing of this transaction, InNexus will be completing a listing on the TSX Venture Exchange, an affiliate of the Toronto Stock Exchange, through its proposed merger with Cusil Venture Corporation (Symbol: CUS).
(press release expired) (5/6/02)
Immune Network Ltd. (CC:IMM) Announces InNexus Inc. "SuperAntibody" Collaboration
Immune Network Ltd. (OTCBB:IMMKF - news; CDNX:IMM - news) announced today it has granted a sublicense option to InNexus Corporation of Seattle for the application of SuperAntibody technology to Immune Network's monoclonal antibodies hNM01 and 1F7. InNexus is focused on the use of SuperAntibodies, a new technology to engineer increased potency and/or novel properties into monoclonal antibodies.
(press release expired) (12/3/01)
Immune Network Ltd. (CC:IMM) Release: 1F7 Pre-Clinical Study Results Published
Immune Network Ltd. (OTCBB:IMMKF - news; CDNX:IMM. - news) and its collaborators, InNexus Corporation (Seattle, WA) and ImmPheron Inc. (Lexington, KY) announced that the Scandinavian
Journal of Immunology, a peer-reviewed medical journal, has published favorable results regarding the effectiveness of the 1F7 monoclonal antibody in non-human primates (Scand J Immunol 2001 Oct; 54(4):383-395).
(press release expired) (10/10/01)
Now, just to muddy up the picture a bit more one can ask “what is Kentucky famous for?” Those things of course are: horses and the Kentucky Derby. And one can also ask what BOCX was formerly involved in before becoming a biotech company.
It looks to me like they were invested in livestock. I am not certain but do believe horses could be considered livestock, though I would have to qualify that.
From “Whispering Oaks International” (BOCX previous name) SEC filing
o During the six months ended June 30, 2001, the Company transferred livestock with a net book value of $13,128 to a related party as payment in full on advances received by the Company totaling $72,303. The difference of $59,175 has been recorded as a contribution to capital.
All the above of course is just my personal DD and attempting to connect the dots. These are my perception only and no one should make a decision based on other peoples DD. I do believe though that anyone investing should ask some tough questions to the companies involved. |
